<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702737</url>
  </required_header>
  <id_info>
    <org_study_id>20200040</org_study_id>
    <nct_id>NCT04702737</nct_id>
  </id_info>
  <brief_title>A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer</brief_title>
  <official_title>A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Delta-like Protein 3 Half-life Extended Bispecific T-cell Engager AMG 757 in Subjects With De Novo or Treatment Emergent Neuroendocrine Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of AMG 757 and will determine the maximum tolerated&#xD;
      dose (MTD) or recommended phase 2 dose (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2021</start_date>
  <completion_date type="Anticipated">September 12, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who Experience One or More Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience One or More Treatment-related Adverse Events</measure>
    <time_frame>Day 1 to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience a Clinically Significant Change from Baseline in Vital Signs</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECG) Measurements</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants who Experience Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response (OR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>OR will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of AMG 757</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of AMG 757</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of AMG 757</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Ratio of AMG 757</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of AMG 757</measure>
    <time_frame>Baseline to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neuroendocrine Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The maximum tolerated dose (MTD) will be estimated using isotonic regression (Ji et al, 2010). The recommended phase 2 dose (RP2D) may be identified based on emerging safety data prior to reaching an MTD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will received the recommended phase 2 dose (RP2D) identified in Part 1 (dose exploration) of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 757</intervention_name>
    <description>AMG 757 will be administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Part 1: Dose Exploration</arm_group_label>
    <arm_group_label>Part 2: Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant has provided informed consent prior to initiation of any study specific&#xD;
             activities/procedures.&#xD;
&#xD;
          -  Men aged ≥ 18 years at time of signing the informed consent.&#xD;
&#xD;
          -  Metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC) defined&#xD;
             by histological, immunohistochemistry, or genomic analyses of baseline tumor tissue&#xD;
             (by local assessment) or circulating tumor DNA (ctDNA) (by local assessment) as per&#xD;
             protocol&#xD;
&#xD;
          -  At least 1 line of prior systemic treatment per protocol.&#xD;
&#xD;
          -  For participants with treatment-emergent NEPC or de novo NEPC with histologic evidence&#xD;
             of prostate cancer with neuroendocrine differentiation.&#xD;
&#xD;
          -  Participants with treatment-emergent NEPC or de novo NEPC with histologic evidence of&#xD;
             prostate cancer with neuroendocrine differentiation without a history of bilateral&#xD;
             orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH)&#xD;
             analogue therapy during the course of protocol therapy&#xD;
&#xD;
          -  Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per&#xD;
             Prostate Cancer Working Group 3 (PCWG3) modifications&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2&#xD;
&#xD;
          -  Participants with treated brain metastases are eligible provided they meet defined&#xD;
             criteria&#xD;
&#xD;
          -  Adequate organ function as defined in protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignancy within the past 2 years, with exceptions:&#xD;
&#xD;
               -  Malignancy treated with curative intent and with no known active disease present&#xD;
                  for ≥ 2 years before enrollment and felt to be at low risk for recurrence by the&#xD;
                  treating physician&#xD;
&#xD;
               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease.&#xD;
&#xD;
               -  Adequately treated non-muscle invasive urothelial carcinoma&#xD;
&#xD;
          -  History or presence of hematological malignancies unless curatively treated with no&#xD;
             evidence of disease ≥ 2 years&#xD;
&#xD;
          -  Untreated or symptomatic brain metastases and leptomeningeal disease&#xD;
&#xD;
          -  Anti-tumor therapy within 28 days of study day 1; concurrent use of hormone&#xD;
             deprivation therapy for hormone refractory prostate is permitted; participants on a&#xD;
             stable bisphosphonate or denosumab for ≥ 30 days prior to study day 1 are eligible&#xD;
&#xD;
        Exceptions:&#xD;
&#xD;
          -  Participants who received conventional chemotherapy are eligible if at least 14 days&#xD;
             have elapsed and if all treatment-related toxicities have resolved to Grade ≤ 1&#xD;
&#xD;
          -  Prior palliative radiotherapy must have been completed at least 7 days before the&#xD;
             first dose of AMG 757&#xD;
&#xD;
          -  Participants who received androgen signaling inhibitor are eligible if at least 14&#xD;
             days have elapsed and if all treatment-related toxicity has been resolved to Grade ≤ 1&#xD;
&#xD;
               -  Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or&#xD;
                  any other form of immunosuppressive therapy within 7 days prior study day 1&#xD;
&#xD;
               -  Active autoimmune disease requiring systemic treatment within the past 2 years&#xD;
&#xD;
               -  Known positive test for human immunodeficiency virus (HIV) or hepatitis&#xD;
&#xD;
               -  Unresolved toxicities from prior anti-tumor therapy, defined as not having&#xD;
                  resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0&#xD;
                  grade 0 or 1 (with the exception of alopecia or toxicities that are stable and&#xD;
                  well-controlled)&#xD;
&#xD;
               -  History of hypophysitis or pituitary dysfunction&#xD;
&#xD;
               -  Has evidence of interstitial lung disease or active, non-infectious pneumonitis.&#xD;
&#xD;
               -  Participants on prior DLL3-targeted therapy may be eligible if discussed with&#xD;
                  Amgen medical monitor prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California at San Francisco Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris OBrien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>De novo or treatment emergent neuroendocrine prostate cancer</keyword>
  <keyword>Delta-like protein 3 (DLL3)</keyword>
  <keyword>Non-canonical Notch ligand</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

